GlyCardial Diagnostics

📍 Barcelona, Spain🗓 Founded 2017👥 7 employees💰 Last funded Aug 2019
Biotechnology🌐 glycardial.com
Website LinkedIn
GlyCardial Diagnostics is a spin-off company of the Catalan Institute of Cardiovascular Sciences (ICCC) and the Spanish National Research Council (CSIC) focused on the development of a novel in vitro diagnostic device for myocardial ischemia. The technology is based on the detection of Apo J-Glyc in blood as a biomarker for the early diagnosis of cardiac ischemia and the prediction of patient’s evolution after an ischemic event. GlyCardial Diagnostics was created by scientists Lina Badimon, Judit Cubedo, Teresa Padró and Gemma Vilahur. The company is located at the Hospital de la Santa Creu i Sant Pau Art Nouveau Site in Barcelona. In 2014, it was recognised as one of the most original, impactful technology projects in Spain in the MIT Technology Review awards for innovators under 35.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2017
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Spain
1
Frequently asked questions
Who invested in GlyCardial Diagnostics?
GlyCardial Diagnostics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did GlyCardial Diagnostics last raise funding?
The most recent investment in GlyCardial Diagnostics recorded on gritt.io was in August 2019.
When was GlyCardial Diagnostics founded?
GlyCardial Diagnostics was founded in 2017.
What industry is GlyCardial Diagnostics in?
GlyCardial Diagnostics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is GlyCardial Diagnostics based?
GlyCardial Diagnostics is headquartered in Barcelona, Spain.